MART-1 / Melan-A Antibody

Flow cytometry: 1-2ug/million cells,Immunofluorescence: 1-2ug/ml,Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT

Due to differences in protocols and secondary antibody used, the Melan-A antibody may require titration for optimal performance.

1. FFPE staining is enhanced by boiling sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Antibody A103 is specific for Melan-A (likely an abbreviation for 'melanocyte antigen'), also called MART-1, a unique antigen on melanoma cells recognized by CTLs (cytotoxic T lymphocytes), making it useful as a melanocyte differentiation marker. It is commonly used to identify metastatic tumors of melanocytic origin, as well as perivascular epithelioid cell tumors. Unlike another commonly used Melan-A / MART-1 antibody, M2-7C10, A103 also stains steroid hormone producing cells, making it valuable in identifying adrenocortical carcinomas.

Note: this protein was identified in 1994 by two different labs, one naming it MART-1 (melanoma antigen recognized by T-cells) and the other Melan-A. Both names are commonly used in literature, but clone A103 antibody is generally referred to as being anti-Melan-A.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

2315

Recombinant human protein was used as the immunogen for the Melan-A antibody.

This Melan-A antibody is available for research use only, not for diagnostic or therapeutic testing.

Cytoplasmic

Protein G affinity chromatography

Human, Mouse, Rat